Clinical Trials Logo

Clinical Trial Summary

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.


Clinical Trial Description

Rosacea is a common inflammatory skin disease affecting up to 10% of adults. Despite this, the etiology of rosacea is unclear, although there may be a genetic predisposition (Chang et al., 2015). Currently, there is no cure. Rosacea can lead to scarring, itching, burning, and is associated with anxiety and depression (Moustafa et al., 2015), significantly affecting quality of life.

Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) that is involved in inflammation. When IL-17A is bound to secukinumab, it cannot bind to its receptor, thereby inhibiting its ability to feed the inflammatory response. In clinical trials, secukinumab has been effective for moderate to severe psoriasis (Blauvelt et al., 2015). Recently, human data from all types of rosacea have shown Th1/Th17 polarization profile of the T-cell response, suggesting that anti-IL-17 therapy may be beneficial for rosacea (Buhl et al., 2015). Hence, secukinumab could be effective against rosacea. This proposal is a proof-of-concept study to use secukinumab in open label design for moderate to severe papulopustular rosacea. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03079531
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 21, 2017
Completion date January 25, 2019

See also
  Status Clinical Trial Phase
Completed NCT03276936 - A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea Phase 3
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT01555463 - Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Phase 3
Active, not recruiting NCT03667222 - Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea Phase 2
Terminated NCT03564145 - A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05150587 - Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT05343455 - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) Phase 3
Completed NCT01872715 - Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Phase 4
Completed NCT01784133 - A Twelve Week Safety and Efficacy Study in Rosacea Phase 2
Completed NCT05296629 - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. Phase 3
Completed NCT05838170 - Study of TP-04 in Participants With Papulopustular Rosacea Phase 2
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Recruiting NCT03864978 - Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test Phase 2
Completed NCT03564119 - A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea Phase 3
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT03448939 - A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05675501 - Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Phase 1
Withdrawn NCT03883945 - A Safety and Efficacy Study to Evaluate Rosacea Phase 1/Phase 2